292 related articles for article (PubMed ID: 12653166)
1. Safety of inhalant allergen immunotherapy with mass units-standardized extracts.
Nettis E; Giordano D; Pannofino A; Ferrannini A; Tursi A
Clin Exp Allergy; 2002 Dec; 32(12):1745-9. PubMed ID: 12653166
[TBL] [Abstract][Full Text] [Related]
2. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
[TBL] [Abstract][Full Text] [Related]
4. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
[TBL] [Abstract][Full Text] [Related]
5. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
[TBL] [Abstract][Full Text] [Related]
6. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study.
Arshad SH; Tariq SM; Matthews S; Hakim E
Pediatrics; 2001 Aug; 108(2):E33. PubMed ID: 11483843
[TBL] [Abstract][Full Text] [Related]
7. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
8. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.
Winther L; Arnved J; Malling HJ; Nolte H; Mosbech H
Clin Exp Allergy; 2006 Mar; 36(3):254-60. PubMed ID: 16499635
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment.
González P; Florido F; Sáenz de San Pedro B; de la Torre F; Rico P; Martín S
J Investig Allergol Clin Immunol; 2002; 12(4):263-71. PubMed ID: 12926186
[TBL] [Abstract][Full Text] [Related]
10. The safety of allergen immunotherapy (IT) in Turkey.
Dursun AB; Sin BA; Oner F; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(2):123-8. PubMed ID: 16689186
[TBL] [Abstract][Full Text] [Related]
11. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
12. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis].
Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357
[No Abstract] [Full Text] [Related]
13. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
14. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
15. Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy.
Arifhodzic N; Behbehani N; Duwaisan AR; Al-Mosawi M; Khan M
Int Arch Allergy Immunol; 2003 Nov; 132(3):258-62. PubMed ID: 14646387
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma.
Duman Senol H; Topyildiz E; Ekici B; Gulen F; Demir E
Int J Pediatr Otorhinolaryngol; 2022 Nov; 162():111292. PubMed ID: 36007303
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
18. [Safety of immunotherapy and skin tests with allergens in children younger than five years].
Rodríguez Pérez N; Ambriz Moreno Mde J
Rev Alerg Mex; 2006; 53(2):47-51. PubMed ID: 16884027
[TBL] [Abstract][Full Text] [Related]
19. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
20. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients.
Rogala B; Markiewicz-Bendkowska IB; Brzoza Z; Glück J; Oleś E
Rhinology; 2007 Jun; 45(2):134-9. PubMed ID: 17708460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
